ATE367390T1 - Phenylalanin enamidderivate - Google Patents

Phenylalanin enamidderivate

Info

Publication number
ATE367390T1
ATE367390T1 AT03740814T AT03740814T ATE367390T1 AT E367390 T1 ATE367390 T1 AT E367390T1 AT 03740814 T AT03740814 T AT 03740814T AT 03740814 T AT03740814 T AT 03740814T AT E367390 T1 ATE367390 T1 AT E367390T1
Authority
AT
Austria
Prior art keywords
compounds
diseases
enamide derivatives
phenylalanine enamide
phenylalanine
Prior art date
Application number
AT03740814T
Other languages
English (en)
Inventor
Julien Alistair Brown
Stuart Bailey
Stephen Brand
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Application granted granted Critical
Publication of ATE367390T1 publication Critical patent/ATE367390T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03740814T 2002-07-17 2003-07-16 Phenylalanin enamidderivate ATE367390T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0216571.0A GB0216571D0 (en) 2002-07-17 2002-07-17 Chemical compounds

Publications (1)

Publication Number Publication Date
ATE367390T1 true ATE367390T1 (de) 2007-08-15

Family

ID=9940613

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03740814T ATE367390T1 (de) 2002-07-17 2003-07-16 Phenylalanin enamidderivate

Country Status (10)

Country Link
US (1) US6835738B1 (de)
EP (1) EP1525204B1 (de)
JP (1) JP4451777B2 (de)
AT (1) ATE367390T1 (de)
AU (1) AU2003280965B2 (de)
CA (1) CA2492430A1 (de)
DE (1) DE60315032T2 (de)
ES (1) ES2290477T3 (de)
GB (1) GB0216571D0 (de)
WO (1) WO2004007494A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061661A2 (en) 2000-10-19 2002-08-08 Target Discovery, Inc. Methods for determining protein and peptide terminal sequences
IL156915A0 (en) * 2001-02-22 2004-02-08 Celltech R&D Ltd Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors
US20070161670A1 (en) * 2006-01-09 2007-07-12 Bristol-Myers Squibb Company Process for the preparation of substituted heterocycles
GB0605766D0 (en) * 2006-03-22 2006-05-03 Ucb Sa Process
WO2008103378A2 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
AU2012325017A1 (en) 2011-10-17 2014-04-17 Westfaelische Wilhelms-Universitaet Muenster Assessment of PML risk and methods based thereon
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
CN112969687A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
CA3115830C (en) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN114222730A (zh) 2019-08-14 2022-03-22 吉利德科学公司 用于抑制α4β7整合素的化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001248553A1 (en) * 2000-04-17 2001-10-30 Celltech R And D Limited Enamine derivatives as cell adhesion molecules
IL156915A0 (en) 2001-02-22 2004-02-08 Celltech R&D Ltd Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors

Also Published As

Publication number Publication date
AU2003280965B2 (en) 2008-10-09
JP4451777B2 (ja) 2010-04-14
EP1525204A1 (de) 2005-04-27
EP1525204B1 (de) 2007-07-18
JP2005536505A (ja) 2005-12-02
CA2492430A1 (en) 2004-01-22
DE60315032D1 (de) 2007-08-30
GB0216571D0 (en) 2002-08-28
AU2003280965A1 (en) 2004-02-02
ES2290477T3 (es) 2008-02-16
WO2004007494A1 (en) 2004-01-22
US6835738B1 (en) 2004-12-28
DE60315032T2 (de) 2008-04-10

Similar Documents

Publication Publication Date Title
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
ATE367390T1 (de) Phenylalanin enamidderivate
NO20051962L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
ATE365742T1 (de) 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren
PT1373263E (pt) Compostos heterociclicos para complicacoes relacionadas com a idade e complicacoes vasculares diabeticas
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
EP1248612A4 (de) Neue substanzen und verbindungen als protease-inhibitoren
DE60315492D1 (de) Medizinisch verwendbare arylethanolamin verbindungen
JO2371B1 (en) 4-phenyl-pyridine derivatives
SE0202462D0 (sv) Novel use
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
BR9709959A (pt) Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
IS8175A (is) Píperasín afleiður og aðferðir við notkun þeirra
NO20052182L (no) Nye forbindelser
TR200101120T2 (tr) Serin proteaz inhibitörü
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
GB0112348D0 (en) Compounds
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
IL156827A (en) Derivatives of 2-mercapto- [3,1] thiazolo [4,5 [b- pyridine and pharmaceutical preparations containing them for the treatment of cardiovascular disease
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
NO20043115L (no) Substituerte diketopiperaziner som oksytocin antagonister

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties